A new study led by Femke Rutters found that too much or too less sleep increases the risk of type 2 diabetes (T2D) in future, a phenomenon associated only with men. Researchers observed sleep duration and diabetes risk factors of 788 individuals aged between 30 and 60 years, from 14 European countries. The men who slept the least time or long time had an increased risk of inability to process glucose and were at higher blood sugar levels. The study concludes that even though an individual is healthy, he is at risk if he sleeps too long hours or sleeps too little hours. Healthy sleep duration is between 7.5 to 9 hours. Femke Rutters, VU Medical Center, Amsterdam is the senior author of the study and the study findings were published in the Journal of the Clinical Endocrinology & Metabolism.
A three-year-long study published in the Annals of Internal Medicine says the study found a treatment for NASH (a fatty liver disease, nonalcoholic steatohepatitis) in diabetes patients. The study has found that 58 percent of individuals experienced reduced NASH activity and 51 percent of individuals have no NASH activity after getting treatment with Pioglitazone diabetes drug. Two to five percent of US citizens are being affected with NASH and its development is a risk factor for cirrhosis and liver cancer. Diplomat specialty pharmacy is expecting approval of the drug in 2016 and the treatment may start in 2017. Currently, NASH is not approved by the FDA.
Part of the retina is called macula. Macula gives us most detailed vision abilities. High sugar levels damage blood vessels in the retina. The leaked fluids accumulate in the macula and impairers vision. This condition is called Diabetic Macular Edema (DME). DME can be treated with any of the following drugs.
A new study published in the JAMA Ophthalmology has found that bevacizumab drug is a cheaper drug when compared with aflibercept (31 times more expensive) and ranibizumab (20 times more expensive) but aflibercept was the most effective drug in treating DME.
A clinical trial led by Dr. Kenneth Cusi from the University of Florida found that Pioglitazone diabetes drug is safe and effective in treating some patients suffering from NASH liver disease. There are no medical treatments or drugs to treat this disease. NASH or non-alcoholic steatohepatitis is a silent liver disease caused due to fat buildup in the liver. NASH can lead to liver cancer or cirrhosis. Obese individuals with type 2 diabetes (T2D) are at a risk and early diagnosis and treatment are required for this disease. The findings are published in the journal Annals of Internal Medicine.
33 percent of the Americans are obese and it is expected to be 50 percent by 2030. Nonalcoholic Fatty Liver Disease (NAFLD) is a chronic liver disease which is associated with diabetes and obesity. NAFLD is caused because of the accumulation of extra fat in the liver. A severe form of NAFLD is called Nonalcoholic Steatohepatitis (NASH), a "silent" liver disease. NASH causes liver inflammation and liver tissue injury and finally damages the liver. Liver damage increases the risk of liver cancer or failure of liver or death. Studies could not find out the causes for NASH but the some of the risk factors are.
There are no drugs or treatment for the NASH. An individual with high disease risk factors can prevent the disease with lifestyle changes, diet control and regular exercise.
Clinical trials show a prescribed treatment option for the Diabetic Macular Edema (DME) by injecting anti-VEGF agents. But a study done by Brian L VanderBeek MD MPH (Physician at the Hospital of the University of Pennsylvania), found that most of the patients were undertreated or not treated early to prevent the development of vision loss. Patients are taking 3.6 anti-VEGF injection drugs on an average when 9 to 10 injections were prescribed.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.